Fore Bio Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 39

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $75M

  • Investors
  • 16

Fore Bio General Information

Description

Operator of a clinical-stage biotechnology company intended to develop selective medicines for functionally and genomically defined cancer patients. The company's clinical-stage drug development aids in recapitulating naturally occurring mutations in vitro and tests their effect on signaling pathway activity and their response to different compounds, enabling biopharma companies to get support in identifying new target mutations and expanding subgroups of cancer patients to respond to existing therapies.

Contact Information

Website
www.fore.bio
Formerly Known As
NovellusDx
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 3675 Market Street
  • Suite 200
  • Philadelphia, PA 19104
  • United States
+1 (267) 000-0000

Fore Bio Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Fore Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC (Series D) 09-Aug-2023 $75M 00000 Completed Clinical Trials - Phase 1
10. Secondary Transaction - Private 01-Jul-2023 000.00 Completed Clinical Trials - Phase 1
9. Later Stage VC 17-Oct-2022 00.000 000.00 Completed Clinical Trials - Phase 1
8. Later Stage VC (Series C) 01-Feb-2022 000.00 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series C) 21-Sep-2020 0000 000.00 Completed Clinical Trials - Phase 1
6. Merger/Acquisition 17-Dec-2018 Cancelled Clinical Trials - Phase 1
5. Later Stage VC 30-Apr-2018 000 000.00 00.00 Completed Clinical Trials - Phase 1
4. Grant 31-Jan-2017 00000 000.00 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series A) 22-Jun-2016 $12.5M $17.6M 000.00 Completed Clinical Trials - Phase 1
2. Seed Round 01-Jan-2014 $1.14M $5.14M Completed Clinical Trials - Phase 1
To view Fore Bio’s complete valuation and funding history, request access »

Fore Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biotechnology company intended to develop selective medicines for functionally and genomica
Drug Discovery
Philadelphia, PA
39 As of 2024
00000
00000000000 00000

000000

derit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur
0000000000000
Gaithersburg, MD
00 As of 0000
00000
00000000 00000

00000

ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in vo
0000 000000000
Boston, MA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Fore Bio Competitors (56)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
Pyxis Oncology Formerly VC-backed Boston, MA 00 00000 000000000 00000
Abcuro Venture Capital-Backed Newton, MA 00 00000 000000 - 000 00000
Erasca Formerly VC-backed San Diego, CA 000 00.000 00000000 00.000
Alterome Therapeutics Venture Capital-Backed San Diego, CA 00 00000 00000000000 00000
You’re viewing 5 of 56 competitors. Get the full list »

Fore Bio Executive Team (13)

Name Title Board Seat Contact Info
Jeff Sacher Chief Financial Officer
Michael Vidne Ph.D Chief Business Officer & Chief Strategy Officer
Gabi Tarcic Ph.D Chief Technology Officer
Gilad Moran Executive Director
Stacie Shepherd MD Chief Medical Officer
You’re viewing 5 of 13 executive team members. Get the full list »

Fore Bio Board Members (18)

Name Representing Role Since
Asaf Shinar Pontifax Venture Capital Board Member 000 0000
Chandra Leo MD HBM Partners Board Member 000 0000
Dieter Weinand Self Chairman 000 0000
Erez Chimovits OrbiMed Board Member 000 0000
Giovanni Mariggi Ph.D Medicxi Board Member 000 0000
You’re viewing 5 of 18 board members. Get the full list »

Fore Bio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Fore Bio Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Medicxi Venture Capital Minority 000 0000 000000 0
Samsung Securities Corporation Minority 000 0000 000000 0
Cormorant Asset Management Hedge Fund Minority 000 0000 000000 0
HBM Healthcare Investments Venture Capital Minority 000 0000 000000 0
HBM Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

Fore Bio FAQs

  • When was Fore Bio founded?

    Fore Bio was founded in 2011.

  • Who is the founder of Fore Bio?

    Haim Gil-Ad and Yoram Altschuler Ph.D are the founders of Fore Bio.

  • Who is the CEO of Fore Bio?

    William Hinshaw is the CEO of Fore Bio.

  • Where is Fore Bio headquartered?

    Fore Bio is headquartered in Philadelphia, PA.

  • What is the size of Fore Bio?

    Fore Bio has 39 total employees.

  • What industry is Fore Bio in?

    Fore Bio’s primary industry is Drug Discovery.

  • Is Fore Bio a private or public company?

    Fore Bio is a Private company.

  • What is Fore Bio’s current revenue?

    The current revenue for Fore Bio is 00000.

  • How much funding has Fore Bio raised over time?

    Fore Bio has raised $157M.

  • Who are Fore Bio’s investors?

    Medicxi, Samsung Securities, Cormorant Asset Management, HBM Healthcare Investments, and HBM Partners are 5 of 16 investors who have invested in Fore Bio.

  • Who are Fore Bio’s competitors?

    NexImmune, Pyxis Oncology, Abcuro, Erasca, and Alterome Therapeutics are some of the 56 competitors of Fore Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »